According to Gram Research analysis of a 2026 international expert consensus, 30 experts from 10 countries agreed on how to treat MetALD, a fatty liver condition driven by both metabolic health problems and alcohol use. Their guidance recommends checking heart and metabolic health, tracking drinking over time, and tailoring alcohol goals and weight loss plans to each person.

A new international expert consensus, reviewed by Gram Research analysis, gives doctors a practical plan for a liver condition called MetALD. MetALD is fatty liver disease that develops in people who have metabolic health problems, such as high blood sugar, high blood pressure, or extra body fat, and who also drink alcohol. Because the condition has been studied less than others, 30 experts from 10 countries used a structured voting process to agree on guidance. Their recommendations include checking heart and metabolic health, tracking alcohol use over time, measuring liver scarring with simple noninvasive tests, and tailoring alcohol goals to each person. The experts also advised weight loss, regular physical activity, and treatment for diabetes, cholesterol, and blood pressure. The guidance is not yet based on large clinical trials, so it should be seen as expert opinion rather than settled proof.

Key Statistics

A 2026 international expert consensus of 30 specialists from 10 countries found that all 33 proposed statements on managing MetALD reached agreement, with 31 meeting the standard in the first round.

In the same 2026 Delphi study, 29 of 30 experts (97%) completed the second round of voting, showing strong engagement in the consensus process.

The consensus defined agreement as a median rating of at least 4 on a 5-point scale, with at least 70% of experts rating a statement in the 4 to 5 range.

The Quick Take

  • What they studied: How doctors should diagnose, monitor, and treat a fatty liver condition that is driven by both metabolic health problems and alcohol use, and when liver transplant may be considered.
  • Who participated: A panel of 30 experts from 10 countries, including specialists from different medical fields who care for people with liver disease. Twenty-nine of the 30 experts stayed in the process for the second round of voting.
  • Key finding: The experts reached agreement on all 33 proposed statements. In the first round, 31 of 33 statements met the agreement standard right away, and the remaining two were revised and voted on again until everyone agreed.
  • What it means for you: If you have fatty liver and also drink alcohol or have blood sugar, blood pressure, or cholesterol concerns, your care may be most effective when these issues are treated together. Talk with your doctor about a plan that addresses both your drinking and your metabolic health.

The Research Details

This research used a modified Delphi process, a structured method for building expert agreement when clear evidence is limited. The team first reviewed the existing medical literature and wrote a set of statements about how MetALD should be handled. The statements were grouped into four areas: diagnosis and disease staging, alcohol use assessment and treatment, metabolic and heart-related care, and liver transplant evaluation.

Experts then rated each statement on a five-point scale, from strong disagreement to strong agreement. A statement counted as agreed upon only when the median score was 4 or higher, at least 70% of ratings fell in the 4 to 5 range, and the ratings were closely clustered. Statements that did not pass in the first round were revised and voted on again in a second round.

This approach lets people with different types of expertise share their views in a fair and organized way. It is especially useful for topics where large studies have not yet answered every practical question.

MetALD is a newer category of liver disease, and many doctors are unsure how to classify it or which treatments to prioritize. Because there are few large trials specific to this group, a structured expert consensus offers a shared set of working rules that clinicians can use while better evidence is gathered.

The Delphi method also reduces the influence of any single expert. Each person rates statements anonymously and sees how the group responded, which encourages thoughtful reconsideration rather than rushed opinions.

The panel was international, multidisciplinary, and had a high retention rate, with 97% of experts completing the second round. The agreement standards were defined in advance, which makes the process more transparent. However, this is an expert opinion process rather than a clinical trial, so the recommendations reflect what specialists believe is best based on current knowledge. Their guidance still needs testing in real-world studies to confirm that it improves patient outcomes.

What the Results Show

The experts agreed that MetALD has two main drivers working together: the metabolic problems that also cause fatty liver disease, and the effects of alcohol on the liver. Because of this overlap, they recommended that doctors check a person’s heart and metabolic health as a routine part of care, rather than focusing only on drinking.

For measuring alcohol use, the panel recommended tracking how much a person drinks over time instead of relying on a single conversation. They also supported using certain direct alcohol tests, which detect recent alcohol use in the body, but only when they are needed. Experts recommended these tests selectively rather than for everyone.

To assess liver scarring, the experts endorsed a step-by-step approach that begins with simple, noninvasive tests. More involved testing is reserved for people whose results suggest higher risk. This approach aims to reduce the need for invasive procedures like liver biopsies when they are not necessary.

For treatment, the panel recommended a personalized plan. Goals for alcohol may range from cutting back to stopping completely, and treatment for alcohol use disorder should follow evidence-based options. Lifestyle support, weight loss, physical activity, and control of diabetes, cholesterol, and blood pressure were all identified as core parts of care.

The panel also addressed liver transplant evaluation. They concluded that decisions should be individualized and made by a team of specialists rather than by a fixed set of rules. This reflects the complexity of balancing liver health, alcohol use, and overall medical needs.

The high level of agreement, with all statements eventually approved, suggests that the experts shared a common view of how to approach this condition. This shared direction may help standardize care across different countries and clinics.

Fatty liver disease has long been recognized as strongly linked to metabolic problems such as obesity, type 2 diabetes, and high cholesterol. Separately, heavy alcohol use is well known to damage the liver. MetALD sits where these two paths overlap, and this consensus builds on both bodies of knowledge.

The guidance also reflects a broader shift in liver medicine toward treating the whole person, including heart health, blood sugar, and alcohol use, rather than treating the liver in isolation. Because MetALD-specific research is still limited, this consensus fills a practical gap while larger studies are underway.

This consensus reflects expert opinion, not the results of a large clinical trial, so it cannot prove that following these recommendations leads to better health outcomes. The experts’ views may also be shaped by their own clinical experience and by the research available to them at the time.

The panel had 30 members from 10 countries, which is a useful group size but may not capture every perspective, especially from regions with different healthcare systems or patient populations. The authors themselves note that the recommendations need external validation and further clinical research before they can be considered definitive.

The Bottom Line

Research shows that a combined approach is the expert standard for MetALD: check metabolic and heart health, track alcohol use over time, use simple tests to assess liver scarring, and tailor treatment goals to each person. Confidence is high that treating metabolic problems and alcohol use together is the sensible approach, given the strong agreement among the 30 experts. Confidence is more moderate for specific thresholds and test choices, since these are based largely on expert judgment rather than large trials.

This guidance is most relevant to doctors, nurses, and other healthcare professionals who treat people with fatty liver disease, as well as people who have been told they have fatty liver and also drink alcohol or have diabetes, high blood pressure, or high cholesterol. People with no liver disease or no alcohol concerns may find the general lifestyle advice useful, but the detailed clinical recommendations are designed for diagnosed patients and their care teams.

Anyone who should not drink alcohol, such as people with advanced liver disease, should follow their own doctor’s advice rather than general guidance.

Changes in liver fat can take several months to show up on imaging or blood tests, and liver scarring usually changes more slowly, often over a year or longer. Many people notice improvements in energy, blood sugar, and blood pressure within weeks to a few months of healthier habits. Your doctor can help set realistic milestones and recheck your liver health at appropriate intervals.

Frequently Asked Questions

What is MetALD and how is it different from regular fatty liver disease?

MetALD stands for metabolic dysfunction- and alcohol-associated liver disease. It is fatty liver disease that occurs in people with metabolic problems, such as high blood sugar or extra body fat, who also drink alcohol. A 2026 expert consensus of 30 specialists treats it as having both metabolic and alcohol-related causes.

How do doctors recommend treating MetALD?

Experts recommend a combined plan that includes checking heart and metabolic health, tracking alcohol use over time, and setting individualized alcohol goals. Treatment also includes weight loss, regular physical activity, and control of diabetes, cholesterol, and blood pressure, according to a 2026 consensus of 30 experts.

Does a fatty liver linked to drinking need a liver transplant?

Transplant decisions should be individualized and made by a multidisciplinary team, according to a 2026 expert consensus. Experts did not recommend a fixed rule. Instead, they advised weighing liver health, alcohol use, and overall medical needs case by case.

Can I check my liver scarring without a biopsy?

Experts recommend a stepwise approach that starts with simple noninvasive tests to estimate fibrosis, or liver scarring. More involved testing is used only when results suggest higher risk. This approach aims to reduce the need for invasive biopsies when they are not necessary.

Want to Apply This Research?

  • Log your weekly alcohol intake in standard drinks and record it every day, then review your weekly totals each Sunday. Also track body weight once a week, waist size once a month, and blood pressure readings if you have them, so you can see trends over time.
  • Set one specific alcohol goal with your doctor, such as cutting weekly drinks by a set number or having several alcohol-free days each week. Pair it with a simple activity goal, like a 20-minute walk on five days, and log both in the app to see how they support each other.
  • Review trends across three-month periods rather than daily ups and downs. Share your app data with your care team at scheduled visits, and ask them which health numbers, such as liver test results, blood sugar, and blood pressure, should be tracked alongside your habits over the long term.

This article summarizes an expert consensus statement for general information only and is not medical advice. The recommendations describe expert opinion rather than proven treatment results. If you have fatty liver disease, drink alcohol regularly, or have concerns about your liver, talk with a qualified healthcare provider before changing your alcohol use, medications, or treatment plan.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: International expert Delphi consensus on the management of metabolic dysfunction- and alcohol-associated liver disease (MetALD). , Annals of hepatology (2026). PubMed 43057653 | DOI
Topics
MetALD fatty liver disease alcohol-associated liver disease liver health metabolic health expert consensus liver fibrosis alcohol use disorder